Repligen Co. (NASDAQ:RGEN) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 31.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,317 shares of the biotechnology company's stock after purchasing an additional 10,692 shares during the quarter. Natixis Advisors LLC owned approximately 0.08% of Repligen worth $6,379,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of RGEN. Resources Management Corp CT ADV purchased a new position in Repligen in the third quarter valued at $37,000. Quarry LP boosted its position in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Global Retirement Partners LLC raised its position in shares of Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 90 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on RGEN. HC Wainwright reiterated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Finally, Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price for the company. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Repligen has an average rating of "Hold" and a consensus target price of $178.64.

Repligen Stock Performance

NASDAQ:RGEN traded down $2.52 during midday trading on Wednesday, reaching $139.43. The stock had a trading volume of 507,228 shares, compared to its average volume of 651,645. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.83 billion, a P/E ratio of -273.39, a P/E/G ratio of 4.54 and a beta of 0.95. The firm has a fifty day simple moving average of $155.62 and a two-hundred day simple moving average of $148.36. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $187.25.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, equities analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.